Cardinal Health is getting pummeled on mixed results — here's our plan for stock

Cardinal Health delivered mixed fiscal Q3 results: revenue rose 11% to $60.94B but missed the $61.7B consensus, while adjusted EPS of $3.17 beat the $2.79 estimate. The company raised FY2026 adjusted EPS guidance to $10.70-$10.80 from $10.15-$10.35 and lifted adjusted free cash flow outlook to $3.3B-$3.7B, but tariff pressure hit Global Medical Products & Distribution segment profit by 35%. Shares fell more than 6% as the stock remained near its 200-day moving average, prompting a price target cut to $225 from $260.

Analysis

The market is keying off the wrong line item. The near-term disappointment is largely about mix and tariff-sensitive margin pressure in a segment that acts as a profit drag, while the higher-growth businesses are still compounding and carrying the valuation narrative. That creates a classic “good core, bad optics” setup: if investors extrapolate the quarter’s operating noise into the outer years, they’ll over-discount cash flow that is likely to be more resilient than the headline suggests.

The bigger second-order effect is competitive. If Cardinal keeps prioritizing simplification, supplier terms, and brand mix, it can defend share without needing broad-based volume acceleration; that usually hurts smaller distributors and contract manufacturers with less scale to absorb tariff volatility. The other segment’s growth profile matters more than it looks on the surface because a high-margin, faster-growing annex to the core distribution business can re-rate the whole story if it keeps compounding for 2-4 quarters.

The risk is that the market is not yet convinced the guide-up is truly operational, so the stock could stay technically weak even if fundamentals improve. Oversold can stay oversold when revisions are front-end loaded by non-operating items and when the most tariff-exposed line still carries margin compression risk into the next reporting cycle. The reversal trigger is a cleaner beat on segment profit in the tariff-sensitive business, plus evidence that volume normalization in the core distribution franchise is stabilizing rather than merely mixing around.

Consensus may be underestimating how much of the long-term upside is embedded in capital returns and cash conversion, not top-line growth. If free cash flow continues to surprise while buybacks stay active, the equity can grind higher even without a clean revenue acceleration. But with the stock near a key technical support area, the better trade is to wait for either stabilization in the next 1-3 weeks or a lower entry after forced-selling exhausts.

Key Decisions for Investors

• Avoid adding to CAH immediately; wait 1-3 weeks for post-earnings digestion or for the 200-day moving average to reclaim on volume before initiating risk.
• If long CAH is desired, use a staged entry: 50% size now only after a daily close back above support, with a 6-8% stop below the recent low; upside is roughly 15-20% if the market re-prices the guide-up as durable.
• Pair trade: long CAH / short a more tariff-exposed medical supply or distribution peer over the next 1-2 quarters; CAH has the stronger cash-flow backstop and better buyback support if margin dispersion widens.
• For tactical investors, buy CAH call spreads with 3-6 month tenor only on further weakness; the risk/reward improves if implied volatility stays elevated while the stock remains oversold.
• Monitor the next quarterly update for segment-profit bridge detail in the tariff-sensitive business; if margin stabilizes, add aggressively, because the stock is likely discounting a worse operating trajectory than the company is actually signaling.